Hemamalini Ketha1, Tom D Thacher2, Sara S Oberhelman3, Philip R Fischer4, Ravinder J Singh5, Rajiv Kumar6. 1. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, United States; Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, United States. 2. Department of Family Medicine, Mayo Clinic, Rochester, MN, 55905, United States. Electronic address: thacher.thomas@mayo.edu. 3. Department of Family Medicine, Mayo Clinic, Rochester, MN, 55905, United States. 4. Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, 55905, United States. 5. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, United States. 6. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, United States; Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, United States; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, 55905, United States.
Abstract
OBJECTIVE:Supplementing lactating mothers with high doses ofvitamin D3 can adequately meet vitamin D requirements of the breastfed infant. We compared the effect of bolus versus daily vitamin D3 dosing in lactating mothers on vitamin D3 catabolism. We hypothesized that catabolism of 25(OH)D3 to 24,25(OH)2D3 would be greater in the bolus than in the daily dose group. DESIGN, SETTING AND PATIENTS: Randomized controlled trial (clinicaltrials.govNCT01240265) in 40 lactating women. INTERVENTIONS: Subjects were randomized to receive vitamin D3 orally, either a single dose of 150,000IU or 5000IU daily for 28days. Vitamin D metabolites were measured in serum and breast milk at baseline, 1, 3, 7, 14 and 28days. MAIN OUTCOME MEASURE: Temporal changes in the serum 24,25(OH)2D3/25(OH)D3 ratio. RESULTS: The concentration of serum 24,25(OH)2D3 was directly related to that of 25(OH)D in both groups (r2=0.63; p<0.001). The mean (±SD) 24,25(OH)2D3/25(OH)D3 ratio remained lower at all time points than baseline values in the daily dose group (0.093±0.024, 0.084±0.025, 0.083±0.024, 0.080±0.020, 0.081±0.023, 0.083±0.018 at baseline, 1, 3, 7, 14, and 28days, respectively). In the single dose group, the increase in 24,25(OH)2D3 lagged behind that of 25(OH)D, but the 24,25(OH)2D3/25(OH)D3 values (0.098±0.032, 0.067±0.019, 0.081±0.017, 0.092±0.024, 0.103±0.020, 0.106±0.024, respectively) exceeded baseline values at 14 and 28days and were greater than the daily dose group at 14 and 28days (p=0.003). The 24,25(OH)2D3/25(OH)D3 ratio remained in the normal range with both dosing regimens. Greater breast milk vitamin D3 values in the single dose group were inversely associated with the 24,25(OH)2D3/25(OH)D3 ratio (r2=0.14, p<0.001), but not with daily dosing. CONCLUSIONS: After a 14-day lag, a single high dose of vitamin D led to greater production of 24,25(OH)2D3, presumably via induction of the 24-hydroxylase enzyme (CYP24A1), relative to the 25(OH)D3 value than did daily vitamin D supplementation, and this effect persisted for at least 28days after vitamin D administration. A daily dose of vitamin D may have more lasting effectiveness in increasing 25(OH)D3 with lesser diversion of 25(OH)D3 to 24,25(OH)2D3 than does larger bolus dosing.
RCT Entities:
OBJECTIVE: Supplementing lactating mothers with high doses of vitamin D3 can adequately meet vitamin D requirements of the breastfed infant. We compared the effect of bolus versus daily vitamin D3 dosing in lactating mothers on vitamin D3 catabolism. We hypothesized that catabolism of 25(OH)D3 to 24,25(OH)2D3 would be greater in the bolus than in the daily dose group. DESIGN, SETTING AND PATIENTS: Randomized controlled trial (clinicaltrials.govNCT01240265) in 40 lactating women. INTERVENTIONS: Subjects were randomized to receive vitamin D3 orally, either a single dose of 150,000IU or 5000IU daily for 28days. Vitamin D metabolites were measured in serum and breast milk at baseline, 1, 3, 7, 14 and 28days. MAIN OUTCOME MEASURE: Temporal changes in the serum 24,25(OH)2D3/25(OH)D3 ratio. RESULTS: The concentration of serum 24,25(OH)2D3 was directly related to that of 25(OH)D in both groups (r2=0.63; p<0.001). The mean (±SD) 24,25(OH)2D3/25(OH)D3 ratio remained lower at all time points than baseline values in the daily dose group (0.093±0.024, 0.084±0.025, 0.083±0.024, 0.080±0.020, 0.081±0.023, 0.083±0.018 at baseline, 1, 3, 7, 14, and 28days, respectively). In the single dose group, the increase in 24,25(OH)2D3 lagged behind that of 25(OH)D, but the 24,25(OH)2D3/25(OH)D3 values (0.098±0.032, 0.067±0.019, 0.081±0.017, 0.092±0.024, 0.103±0.020, 0.106±0.024, respectively) exceeded baseline values at 14 and 28days and were greater than the daily dose group at 14 and 28days (p=0.003). The 24,25(OH)2D3/25(OH)D3 ratio remained in the normal range with both dosing regimens. Greater breast milkvitamin D3 values in the single dose group were inversely associated with the 24,25(OH)2D3/25(OH)D3 ratio (r2=0.14, p<0.001), but not with daily dosing. CONCLUSIONS: After a 14-day lag, a single high dose of vitamin D led to greater production of 24,25(OH)2D3, presumably via induction of the 24-hydroxylase enzyme (CYP24A1), relative to the 25(OH)D3 value than did daily vitamin D supplementation, and this effect persisted for at least 28days after vitamin D administration. A daily dose of vitamin D may have more lasting effectiveness in increasing 25(OH)D3 with lesser diversion of 25(OH)D3 to 24,25(OH)2D3 than does larger bolus dosing.
Authors: Martin Kaufmann; J Christopher Gallagher; Munro Peacock; Karl-Peter Schlingmann; Martin Konrad; Hector F DeLuca; Rita Sigueiro; Borja Lopez; Antonio Mourino; Miguel Maestro; René St-Arnaud; Joel S Finkelstein; Donald P Cooper; Glenville Jones Journal: J Clin Endocrinol Metab Date: 2014-03-26 Impact factor: 5.958
Authors: Puja J Umaretiya; Sara S Oberhelman; Elizabeth W Cozine; Julie A Maxson; Stephanie M Quigg; Tom D Thacher Journal: Ann Fam Med Date: 2017-01-06 Impact factor: 5.166
Authors: Sara S Oberhelman; Michael E Meekins; Philip R Fischer; Bernard R Lee; Ravinder J Singh; Stephen S Cha; Brian M Gardner; John M Pettifor; Ivana T Croghan; Tom D Thacher Journal: Mayo Clin Proc Date: 2013-12 Impact factor: 7.616
Authors: Peter J Tebben; Dawn S Milliner; Ronald L Horst; Peter C Harris; Ravinder J Singh; Yanhong Wu; John W Foreman; Paul R Chelminski; Rajiv Kumar Journal: J Clin Endocrinol Metab Date: 2012-02-15 Impact factor: 5.958
Authors: T Hoogenboezem; H J Degenhart; S M de Muinck Keizer-Schrama; R Bouillon; W F Grose; W H Hackeng; H K Visser Journal: Pediatr Res Date: 1989-06 Impact factor: 3.756
Authors: Karen M O'Callaghan; Mahgol Taghivand; Anna Zuchniak; Akpevwe Onoyovwi; Jill Korsiak; Michael Leung; Daniel E Roth Journal: Adv Nutr Date: 2020-01-01 Impact factor: 8.701
Authors: George Griffin; Martin Hewison; Julian Hopkin; Rose Anne Kenny; Richard Quinton; Jonathan Rhodes; Sreedhar Subramanian; David Thickett Journal: Clin Med (Lond) Date: 2021-02-16 Impact factor: 2.659
Authors: Konstantinos Makris; Harjit P Bhattoa; Etienne Cavalier; Karen Phinney; Christopher T Sempos; Candice Z Ulmer; Samuel D Vasikaran; Hubert Vesper; Annemieke C Heijboer Journal: Clin Chim Acta Date: 2021-03-10 Impact factor: 6.314